Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 134 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Any Condition Clear all

Conditions: Uterine Cancer
Interventions: Imatinib Mesylate, Paclitaxel; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Leptomeningeal Metastasis
Interventions: 186RNL; Drug
Lead sponsor: Cerenome; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Non Clear Cell Renal Cell Carcinoma (nccRCC)
Interventions: lenvatinib, everolimus; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 8
States / cities: Tampa, Florida • Chicago, Illinois • Boston, Massachusetts + 5 more

Conditions: Lung Cancer, Small Cell
Interventions: topotecan; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 6
States / cities: Lebanon, New Hampshire • The Bronx, New York • Philadelphia, Pennsylvania + 3 more

Conditions: Allergy Skin, Allergy, Dermatitis, Allergic Contact
Interventions: NeoMatriX Wound MatriX Collagen Dressing; Device
Lead sponsor: NeXtGen Biologics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Peripheral Vascular Diseases
Interventions: riferminogene pecaplasmid, Placebo (for riferminogene pecaplasmid); Biological
Lead sponsor: Sanofi; Industry
Eligibility: 50 Years and older
Enrollment: 525 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Neuralgia, Postherpetic
Interventions: Lamictal in the treatment of Post-Herpetic Neuralgia; Drug
Lead sponsor: George Washington University; Other
Eligibility: 18 Years to 85 Years
Timeline: Started 2005
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Knee Osteoarthritis
Interventions: Corticosteroid injection; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 40 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV Infections, Hepatitis B
Interventions: Not listed
Lead sponsor: Syneos Health; Other
Eligibility: 12 Years to 60 Years · Female only
Enrollment: 24,258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1989 – 2099
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: There is no Focus on Any Specific Condition
Interventions: Peripheral intravenous catheter placement, Blood draw, Peripheral intravenous catheter, To keep open (TKO) infusion of 0.9% normal saline; Procedure · Other · Device + 1 more
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 90 Years
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Solid Tumor, Metastatic Colorectal Cancer
Interventions: dasatinib, bevacizumab, Oxaliplatin, Capecitabine; Drug
Lead sponsor: Herbert Hurwitz, MD; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 2
States / cities: Denver, Colorado • Durham, North Carolina

Conditions: Pulmonary Fibrosis
Interventions: Not listed
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years to 99 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Glaucoma
Interventions: Xal-Ease device to be used with Xalatan eye drops; Device
Lead sponsor: Augusta University; Other
Eligibility: 40 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: HIV-1-infection
Interventions: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC); Drug
Lead sponsor: The Crofoot Research Center, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
Interventions: LY3410738, Gemcitabine, Cisplatin, Durvalumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 17
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 13 more

Conditions: BiPolar
Interventions: ADASUVE®; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Atlanta, Georgia • Cincinnati, Ohio

Conditions: Hypertension, Pulmonary
Interventions: Adempas (Riociguat, BAY63-2521); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 80 Years
U.S. locations: 24
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 20 more

Conditions: Oropharyngeal Carcinoma
Interventions: 18F-FMISO PET/CT Scan, Chemoradiation, Questionnaires; Diagnostic Test · Combination Product · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Oppositional Defiant Disorder, Conduct Disorder, Attention Deficit/Hyperactivity Disorder (ADHD), Intermittent Explosive Disorder, Impulse-Control Disorders, Adjustment Disorder, Bipolar Disorder, Pervasive Developmental Disorder
Interventions: Risperdal; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 4 Years to 14 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Sleep Apnea, Sleep Disordered Breathing
Interventions: 14 days of placebo therapy, 14 days of CPAP therapy; Device
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 90 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Any Disease Condition and Reportedly-healthy Subjects
Interventions: Not listed
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 100,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2077
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Metastatic Breast Cancer
Interventions: Palbociclib, Fulvestrant, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 521 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 134
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 90 more

Conditions: Hormone Receptor Positive Breast Cancer
Interventions: faslodex 500mg, arimidex 1mg, faslodex dummy, arimidex dummy; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 462 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 12
States / cities: Modesto, California • Savannah, Georgia • Auburn, Maine + 9 more

Conditions: Adult Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm
Interventions: Azacitidine, Laboratory Biomarker Analysis, Oxaliplatin, Pharmacological Study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma

Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease

A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors

NeoMatriX Wound Matrix Collagen Dressing Skin Prick Test

Efficacy and Safety of XRP0038/NV1FGF in Critical Limb Ischemia Patients With Skin Lesions

Lamictal in the Treatment of Post-Herpetic Neuralgia

Do Knee Injections Offer Benefit With Knee Arthritis Pain

Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant People.

Antegrade Versus Retrograde IV for Blood Draws

XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib

Supplemental Oxygen in Pulmonary Fibrosis

Effects of Xal-Ease on Patient Compliance With Xalatan

Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication

Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer

Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone.

Sleepiness and the Effects of CPAP on Salivary Cortisol and Alpha-Amylase Levels in Patients With Sleep Apnea

Precision Genomics Medicine Biobank

Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.

Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy